马来丝虫肌球蛋白29表位基因真核表达质粒及原核表达蛋白免疫小鼠诱导的免疫应答

摘要/Abstract

摘要：

目的观察马来丝虫肌球蛋白29（Brugia malayi myosin 29,BmM29）表位基因真核表达质粒pcDNA3.1（+）-BmM29和原核表达的纯化重组蛋白rBmM29免疫小鼠诱导的免疫应答效果。方法在大肠埃希菌（Escherichia coli）BL21诱导表达重组蛋白rBmM29,纯化后作为重组蛋白疫苗;纯化真核表达重组质粒pcDNA3.1（+）-BmM29作为核酸疫苗。核酸疫苗免疫注射部位为小鼠后腿胫前肌,重组蛋白为皮下多点注射。60只BALB/c小鼠随机分为A、B、C、D、E组,每组12只,分别注射PBS（100 μg）、pcDNA3.1（+）/CpG（100 μg/30 μg）、pcDNA3.1（+）-BmM29/CpG（100 μg/30 μg）、rBmM29/CpG（50 μg/30 μg）、pcDNA3.1（+）-BmM29/rBmM29/CpG（前2次注射pcDNA3.1（+）-BmM29/CpG 100 μg/30 μg,第3次注射rBmM29/CpG 50 μg/30 μg）,共免疫3次,每次免疫间隔2周。初次免疫后第4、6、8周,眼球摘除法采血制备血清,ELISA法检测免疫小鼠血清特异性IgG抗体效价。免疫第8周处死小鼠,制备脾细胞悬液培养48 h,ELISA检测培养上清中细胞因子γ干扰素（IFN-γ）、白细胞介素-4（IL-4）水平。结果 ELISA检测结果显示,A、B、C、D和E组小鼠初次免疫后第4周血清中抗体的吸光度（A₄₉₀值）分别为0.038 ± 0.050、0.053 ± 0.009、0.360 ± 0.035、0.456 ± 0.025、0.370 ± 0.025,第6周分别为0.045 ± 0.003、0.045 ± 0.005、0.510 ± 0.018、0.548 ± 0.010、0.552 ± 0.018,第8周分别为0.041 ± 0.004、0.044 ± 0.009、0.606 ± 0.047、0.674 ± 0.042、0.770 ± 0.041,C、D、E组均高于A、B组（P < 0.05）,第8周时,E组IgG抗体的A₄₉₀值高于C组和D组（P < 0.05）。初次免疫后第8周,A至E组小鼠脾细胞培养上清中IFN-γ的水平分别为（47.72 ± 8.94）、（50.43 ± 2.81）、（304.78 ± 8.42）、（242.28 ± 5.99）、（426.52 ± 6.76）pg/ml,C、D、E组均高于A、B组（P < 0.05）,E组高于C组和D组（P < 0.05）;小鼠脾细胞培养上清中IL-4的水平分别为（60.00 ± 11.14）、（57.71 ± 15.95）、（93.17 ± 12.56）、（96.67 ± 11.48）、（101.17 ± 5.81）pg/ml,C、D、E组均高于A、B组（P < 0.05）。结论 pcDNA3.1（+）-BmM29核酸疫苗和rBmM29重组蛋白均可诱导BALB/c小鼠产生特异性体液和细胞免疫应答,核酸疫苗与重组蛋白疫苗联合免疫效果更佳。

关键词: 马来丝虫, 肌球蛋白29表位基因, 重组蛋白, 基因疫苗, 蛋白疫苗

Abstract:

Objective To determine the immune responses elicited in BALB/c mice by vaccination with eukaryotic expression plasmid pcDNA3.1（+）-BmM29 containing Brugia malayi myosin 29（BmM29） epitode and prokaryotically expressed recombinant BmM2 protein（rBmM29） respectively. Methods rBmM29 protein was expressed in E. coli strain BL21, purified as recombinant protein vaccine, and administered via multiple subcutaneous injections. The purified recombinant plasmid pcDNA3.1（+）-BmM29 was used as the nucleic acid vaccine and injected into the tibialis anterior muscle. Sixty BALB/c mice were randomized to receive three immunizations（with intervals of 2 weeks） with PBS （100 μg, group A）, pcDNA3.1（+）/CpG （100 μg/30 μg, group B）, pcDNA3.1(+)-BmM29/CpG （100 μg/30 μg, group C）, rBmM29/CpG（50 μg/30 μg, group D）, or pcDNA3.1（+）-BmM29/rBmM29/CpG （two injections of pcDNA3.1（+）-BmM29/CpG 100 μg/30 μg followed by a rBmM29/CpG 50 μg/30 μg）. Serum was prepared through ophthalmectomy at week 4, 6, and 8 after primary immunization, and the serum IgG titer was determined by ELISA. The mice were sacrificed at week 8, splenocyte suspension cultured for 48 h, and levels of INF-γ and IL-4 in the supernatant detected by ELISA. Results ELISA results showed that the A₄₉₀ values of serum IgG in groups A-E were 0.038 ± 0.050, 0.053 ± 0.009, 0.360 ± 0.035, 0.456 ± 0.025, 0.370 ± 0.025 at week 4, 0.045 ± 0.003, 0.045 ± 0.005, 0.510 ± 0.018, 0.548 ± 0.010, 0.552 ± 0.018 at week 6, and 0.041 ± 0.004, 0.044 ± 0.009, 0.606 ± 0.047, 0.674 ± 0.042, 0.770 ± 0.041 at week 8, significantly higher in groups C, D and E than in groups A and B （P < 0.05） at all time points, and significantly higher in group E than in groups C and D（P < 0.05） at week 8. The IFN-γ levels in splenocyte culture supernatant at week 8 after primary immunization were （47.72 ± 8.94）, （50.43 ± 2.81）, （304.78 ± 8.42）, （242.28 ± 5.99）, and（426.52 ± 6.76） pg/ml in groups A-E, respectively, significantly higher in groups C-D than in groups A and B（P < 0.05）, and in group E than in groups C and D（P < 0.05）. The IL-4 levels in splenocyte culture supernatant were（60.00 ± 11.14）, （57.71 ± 15.95）, （93.17 ± 12.56）, （96.67 ± 11.48）, and （101.17 ± 5.81） pg/ml, significantly higher in groups C-D than in groups A and B（P < 0.05）. Conclusion Both the recombinant plasmid pcDNA3.19(+)-BmM29 and rBmM29 protein could elicit specific humoral and cellular immune responses in mice. Combined immunization with nucleic acid vaccine and protein vaccine is superior to each of the two alone.

Key words: Brugia malayi, Myosin 29 epitope gene, Recombinant protein, Gene vaccine, Protein vaccine

中图分类号:

R383.161

夏瑜椰, 徐倩, 孙婷婷, 方浩, 刘蔚, 陆施娟, 方政. 马来丝虫肌球蛋白29表位基因真核表达质粒及原核表达蛋白免疫小鼠诱导的免疫应答[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(1): 59-63.

Yu-ye XIA, Qian XU, Ting-ting SUN, Hao FANG, Wei LIU, Shi-juan LU, Zheng FANG. Mouse immune responses elicited by eukaryotic expression plasmid and prokaryotically expressed protein of Brugia malayi myosin 29 epitope[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2017, 35(1): 59-63.

图/表 2

参考文献 17

[1]	张贤昌, 黄少玉, 邓卓晖, 等. 广东省输入性丝虫病病例调查[J]. 中国寄生虫学与寄生虫病杂志, 2008, 26(6): 409-411.
[2]	傅斌, 李桂玲, 胡颖新, 等. 输入性传染源对山东省消除丝虫病影响的调查[J]. 中国寄生虫学与寄生虫病杂志, 2003, 21(2): 96-98.
[3]	Bunnell BA, Morgan RA.Gene therapy for infectious diseases[J]. Clin Microbiol Rev, 1998, 11(1): 42-56.
[4]	谢东方, 方政, 黄为群, 等. 马来丝虫肌球蛋白部分编码基因Bm-M55的克隆与真核表达[J]. 中国寄生虫学与寄生虫病杂志, 2008, 26(6): 482-484.
[5]	谢东方. 方政, 童海燕, 等. 马来丝虫3-磷酸甘油醛脱氢酶基因的克隆、序列分析及编码产物B细胞表位预测[J]. 中国寄生虫学与寄生虫病杂志, 2009, 27(3): 226-228.
[6]	徐倩, 吴佳倩, 张波, 等. 周期型马来丝虫M29表位基因原核及真核表达载体的构建[J]. 中华传染病杂志, 2015, 33(6): 360-362.
[7]	Donnelly JJ, Wahren B, Liu MA.DNA vaccines: progress and challenges[J]. J Immunol, 2005, 175(2): 633-639.
[8]	张赛楠, 方政, 陆施娟, 等. 周期型马来丝虫CPI基因真核表达载体的构建和免疫学研究[J]. 中国寄生虫学与寄生虫病杂志, 2011, 29(6): 434-438.
[9]	Nikolaou S, Hu M, Chilton NB, et al. Class II myosins in nematodes--genetic relationships, fundamental and applied implications[J]. Biotechnol Adv, 2006, 24(3): 338-350.
[10]	李小红, 刘述先, 宋光承, 等. 日本血吸虫肌球蛋白部分重链基因核酸疫苗的构建与小鼠保护性研究[J]. 中国血吸虫病防治杂志, 2005, 17(1): 9-12.
[11]	Chace JH, Hooker NA, Mildenstein KL, et al. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12[J]. Clin Immunol Immunopathol, 1997, 84(2): 185-193.
[12]	Yi AK, Chace JH, Cowdery JS, et al. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides[J]. J Immunol, 1996, 156(2): 558-564.
[13]	Salem AK, Hung CF, Kim TW, et al. Multi-component nanorods for vaccination applications[J]. Nanotechnology, 2005, 16(4): 484-487.
[14]	Mutwiri GK, Nichani AK, Babiuk S, et al. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides[J]. J Control Release, 2004, 97(1): 1-17.
[15]	Stober CB, Lange UG, Roberts MT, et al. Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c mice[J]. Infect Immun, 2007, 75(2): 852-860.
[16]	Shang L, Liu Q, Liu W, et al. Protection in mice immunized with a heterologous prime-boost regime using DNA and recombinant pseudorabies expressing TgSAG1 against Toxoplasma gondii challenge[J]. Vaccine, 2009, 27(21): 2741-2745.
[17]	Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers[J]. Vaccine, 2008, 26(31): 3947-3957.